| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
The primary targets of (E)-tri-Pcoumaroylspermidine include HIV-1 protease (HIV-1 PR), where it acts as an inhibitor. It also shows potent and selective inhibition of the serotonin transporter (SERT), which could improve neuropsychological disorders through regulating serotoninergic transmission. Additionally, it exhibits free radical-scavenging activity and may interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), mimicking the binding poses of known inhibitors like galantamine.
|
|---|---|
| ln Vitro |
(E)-tri-Pcoumaroylspermidine exhibits remarkable hepatoprotective activity, with similar effective dosage to sulforaphane, by inhibiting ethanol-induced apoptosis in HepG2 cells. It shows free radical-scavenging activity. As an HIV-1 PR inhibitor and a serotonin transporter inhibitor, it demonstrates potent and selective activity. It also shows anticholinesterase activity and can bind to AChE and BuChE, serving as a model molecule for future searches for new inhibitors.
|
| ln Vivo |
In vivo studies of (E)-tri-Pcoumaroylspermidine are limited, but its in vitro hepatoprotective activity suggests potential in vivo efficacy in models of alcohol-associated liver disease (ALD). As a serotonin transporter inhibitor, it may have effects on neuropsychological disorders in vivo. Its HIV-1 PR inhibitory activity suggests potential antiviral applications. However, specific in vivo efficacy data in animal models are not detailed in the available literature. Further studies are needed to evaluate its pharmacokinetics and efficacy.
|
| Enzyme Assay |
Typical in vitro assays for (E)-tri-Pcoumaroylspermidine include HIV-1 protease inhibition assays, where the compound is incubated with the enzyme and a fluorogenic substrate, and activity is measured by fluorescence. Serotonin transporter inhibition assays are performed using cells expressing the transporter and measuring radiolabeled serotonin uptake. Antioxidant activity is assessed using DPPH and ABTS radical scavenging assays. For hepatoprotective studies, HepG2 cells are treated with ethanol and the compound, and cell viability is assessed by MTT assay.
|
| Cell Assay |
Cellular assays for (E)-tri-Pcoumaroylspermidine typically involve HepG2 cells for hepatoprotective studies. Cells are treated with ethanol to induce apoptosis and co-treated with the compound at various concentrations (e.g., 1-100 µM) for 24-48 hours. Cell viability is assessed by MTT assay, and apoptosis is evaluated by Annexin V/PI staining and caspase activity measurements. For serotonin transporter studies, cells expressing SERT are treated with the compound, and serotonin uptake is measured. These cell-based systems allow for detailed analysis of the compound's mechanism of action.
|
| Animal Protocol |
In vivo animal experiments for (E)-tri-Pcoumaroylspermidine are not detailed in the available literature. For hepatoprotective studies, typical animal models include alcohol-induced liver injury in mice. The compound would be administered orally or intraperitoneally at doses comparable to sulforaphane, and liver function markers (ALT, AST), histopathology, and apoptosis markers would be assessed. For serotonin transporter studies, animal models of depression or anxiety could be used. However, such studies have not been reported for this specific compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (E)-tri-Pcoumaroylspermidine are limited. As a large, polar molecule with a molecular weight of 583.67 g/mol and a LogP of 3.75, it would be expected to have moderate lipophilicity and potentially reasonable oral bioavailability. However, its amide bonds may be susceptible to enzymatic hydrolysis. Detailed ADME parameters including Cmax, Tmax, half-life, and bioavailability are not available in the consulted sources. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicological data for (E)-tri-Pcoumaroylspermidine are limited. As a naturally occurring plant metabolite, it is generally considered to have low toxicity. It is a spermidine compound present in safflower florets and other plants. Standard laboratory safety precautions should be followed when handling the compound. It is classified as a research compound and is not for human use. No significant toxicity has been reported for this compound.
|
| References | |
| Additional Infomation |
Tristigromynyl spermidine is a conjugate of spermidine and hydroxycinnamic acid, wherein each nitrogen atom of spermidine forms an amide bond with a 4-coumaric acid molecule. It is functionally related to 4-coumaric acid. Tristigromynyl spermidine has been reported to exist in Quercus dentata, Artemisia carvifolia, and several other organisms with relevant data.
(E)-tri-Pcoumaroylspermidine is a naturally occurring hydroxycinnamic acid amide and spermidine conjugate with hepatoprotective, antioxidant, HIV-1 protease inhibitory, and serotonin transporter inhibitory activities. It is found in Carthamus tinctorius L. (safflower) and other plants. It is a research compound used in studies of liver protection, neuropsychology, antiviral activity, and as a model for cholinesterase inhibitors. It is not approved for any clinical indication. |
| Molecular Formula |
C34H37N3O6
|
|---|---|
| Molecular Weight |
583.67
|
| Exact Mass |
583.268
|
| CAS # |
131086-78-7
|
| PubChem CID |
14777879
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
954.2±65.0 °C at 760 mmHg
|
| Flash Point |
530.9±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.666
|
| LogP |
3.75
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
43
|
| Complexity |
926
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
c1cc(ccc1/C=C/C(=O)NCCCCN(CCCNC(=O)/C=C/c2ccc(cc2)O)C(=O)/C=C/c3ccc(cc3)O)O
|
| InChi Key |
PFDVWJCSCYDRMZ-AUCPOXKISA-N
|
| InChi Code |
InChI=1S/C34H37N3O6/c38-29-13-4-26(5-14-29)10-19-32(41)35-22-1-2-24-37(34(43)21-12-28-8-17-31(40)18-9-28)25-3-23-36-33(42)20-11-27-6-15-30(39)16-7-27/h4-21,38-40H,1-3,22-25H2,(H,35,41)(H,36,42)/b19-10+,20-11+,21-12+
|
| Chemical Name |
(E)-3-(4-hydroxyphenyl)-N-[4-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-[3-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]amino]propyl]amino]butyl]prop-2-enamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7133 mL | 8.5665 mL | 17.1330 mL | |
| 5 mM | 0.3427 mL | 1.7133 mL | 3.4266 mL | |
| 10 mM | 0.1713 mL | 0.8566 mL | 1.7133 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
